Shoulder Innovations (SI) Preferred Stock Liabilities (2024 - 2025)
Shoulder Innovations' (SI) quarterly Preferred Stock Liabilities came in at $126.7 million in Q2 2025, up 70.12% on a YoY basis from $74.5 million in Q2 2024, and up 34.58% quarter-over-quarter from $94.1 million in Q1 2025.
Analysis
Shoulder Innovations (SI) Preferred Stock Liabilities (2024 - 2025) Analysis & Trends
Shoulder Innovations (SI) has reported Preferred Stock Liabilities for 2 consecutive years, with $126.7 million the latest figure, recorded in Q2 2025.
- For the quarter ending Q2 2025, Preferred Stock Liabilities rose 70.12% year-over-year to $126.7 million; the trailing twelve-month figure through Jun 2025 stood at $126.7 million (up 70.12% YoY), and the FY2024 full-year result was $74.5 million, changed N/A from the prior year.
- Preferred Stock Liabilities climbed to $126.7 million in Q2 2025 per SI's latest filing, from $94.1 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $126.7 million in Q2 2025 and bottomed at $74.5 million in Q2 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 185.05 Bn | 179.45 Bn | 7.27 Bn | - |
| 2 | Intuitive Surgical | 124.43 Bn | 119.22 Bn | 1.96 Bn | - |
| 3 | Medtronic | 118.52 Bn | 109.70 Bn | 6.34 Bn | - |
| 4 | Stryker | 104.55 Bn | 101.07 Bn | 4.50 Bn | - |
| 5 | Boston Scientific | 67.11 Bn | 66.57 Bn | 3.85 Bn | - |
| 6 | Edwards Lifesciences | 49.85 Bn | 45.60 Bn | 1.35 Bn | - |
| 7 | Alcon | 33.97 Bn | 32.52 Bn | 1.68 Bn | - |
| 8 | Dexcom | 32.28 Bn | 30.33 Bn | 830.00 Mn | - |
| 9 | Steris | 21.15 Bn | 20.67 Bn | 684.20 Mn | - |
| 10 | Shoulder Innovations | 413.68 Mn | 314.68 Mn | 13.44 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2025 | 126.70 Mn |
| Mar 31, 2025 | 94.15 Mn |
| Dec 31, 2024 | 74.48 Mn |
| Sep 30, 2024 | 74.48 Mn |
| Jun 30, 2024 | 74.48 Mn |